Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/28/24
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial GuidancePRNewsWire • 02/28/24
Idorsia and Viatris enter into a significant global research and development collaborationGlobeNewsWire • 02/28/24
Viatris and Idorsia Enter Into Significant Global Research and Development CollaborationPRNewsWire • 02/28/24
Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key MetricsZacks Investment Research • 02/23/24
Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)Seeking Alpha • 01/10/24
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D OfficerPRNewsWire • 12/15/23
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of ShareholdersPRNewsWire • 12/15/23
Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/07/23
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in EuropePRNewsWire • 11/30/23